Effectiveness of Treatments for Bipolar Disorder: A Swedish Study
Introduction
A recent study published in JAMA Psychiatry by Swedish researchers examined the effectiveness of various treatment options for individuals with bipolar disorder. This chronic psychiatric condition is a significant global health issue, ranked as the sixth most common disability by the World Health Organization.
Challenges in Treatment and Remission Rates
While advanced medications have been developed to manage bipolar disorder, the long-term remission rates remain unsatisfactory for many patients undergoing pharmacologic treatment.
Study Overview
The Swedish research team conducted a statistical analysis involving a Finnish cohort to investigate the rates of re-hospitalization among patients diagnosed with bipolar disorder. The study analyzed data from January 1, 1987, to December 31, 2012, focusing on 18,018 Finnish patients. By utilizing a within-subject control design, the researchers aimed to mitigate any selection bias.
Methodology
To ensure the accuracy of the results, the study accounted for common mood stabilizers, including lithium carbonate, risperidone, and 27 other formulations. Additionally, it considered the length of illness and the periods when patients were not receiving medication.
Key Findings
Published this year in JAMA Psychiatry, the study revealed that 54% of participants experienced at least one instance of psychiatric re-hospitalization. Lithium treatment emerged as the medication associated with the lowest risk of re-hospitalization from any cause. In contrast, quetiapine fumarate, the most widely used antipsychotic, demonstrated only moderate effectiveness in preventing psychiatric re-hospitalization. Furthermore, the findings indicated that injectable treatments were more effective than their oral counterparts.
Limitations and Future Directions
The study’s findings are limited to the Finnish population and may be influenced by diagnostic biases. Although the International Classification of Diseases is a recognized system for diagnosing psychiatric disorders, researchers noted its inadequacy for optimizing observational studies. Despite these limitations, lithium and long-acting injectable medications were linked to an approximately 30% reduced risk of re-hospitalization compared to other treatments. The researchers express hope that ongoing improvements in these medications will enhance patient outcomes in the future.
Conclusion
The study underscores the need for continued research into effective treatment options for bipolar disorder, with a particular focus on enhancing the efficacy of long-term pharmacologic therapies.
Reference
Lähteenvuo, M., Tanskanen, A., Taipale, H., Hoti, F., Vattulainen, P., Vieta, E., Tiihonen, J. (2018). Real-World Effectiveness of Pharmacologic Treatments for the Prevention of Rehospitalization in a Finnish Nationwide Cohort of Patients With Bipolar Disorder. JAMA Psychiatry. Published online February 28, 2018. DOI 10.1001/jamapsychiatry.2017.4711.